Physician profile

Manuel Gonzalez

Orlando, FL

NPI 1750429551

$1,712.48

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$50.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Acadia Pharmaceuticals INC $1,434.34 2019-2023 Nuplazid
Teva Pharmaceuticals USA, INC. $67.19 2022
Mdd US Operations, LLC $41.81 2019
Supernus Pharmaceuticals, INC. $33.92 2022
Kyowa Kirin, INC. $27.55 2019
Acorda Therapeutics, INC $24.80 2019
Avion Pharmaceuticals $20.32 2022
Vertical Pharmaceuticals, LLC $19.90 2019
Abbvie INC. $17.71 2022
Boston Scientific Corporation $13.79 2022
Allergan, INC. $11.15 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Manuel Gonzalez

$1,712.48

in general payments reported 2019-2025

Years
2019-2023
Top company
Acadia Pharmaceuticals INC

https://glasscript.com/doctor/351988/manuel-gonzalez

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.